Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome
Top Cited Papers
- 1 May 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Arrhythmia and Electrophysiology
- Vol. 10 (5), e005053
- https://doi.org/10.1161/circep.117.005053
Abstract
Background— There is emerging evidence that localization and elimination of abnormal electric activity in the epicardial right ventricular outflow tract may be beneficial in patients with Brugada syndrome. Methods and Results— A total of 135 symptomatic Brugada syndrome patients having implantable cardiac defibrillator were enrolled: 63 (group 1) having documented ventricular tachycardia (VT)/ventricular fibrillation (VF) and Brugada syndrome–related symptoms, and 72 (group 2) having inducible VT/VF without ECG documentation at the time of symptoms. About 27 patients of group 1 experienced multiple implantable cardiac defibrillator shocks for recurrent VT/VF episodes. Three-dimensional maps before and after ajmaline determined the arrhythmogenic electrophysiological substrate (AES) as characterized by prolonged fragmented ventricular potentials. Primary end point was identification and elimination of AES leading to ECG pattern normalization and VT/VF noninducibility. Extensive areas of AES were found in the right ventricle epicardium, which were wider in group 1 (P=0.007). AES increased after ajmaline in both groups (PP=0.008). The increase of type-1 ST-segment elevation correlated with AES expansion (r=0.682, P<0.001). Radiofrequency ablation eliminated AES leading to ECG normalization and VT/VF noninducibility in all patients. During a median follow-up of 10 months, the ECG remained normal even after ajmaline in all except 2 patients who underwent a repeated effective procedure for recurrent VF. Conclusions— In Brugada syndrome, AES is commonly located in the right ventricle epicardium and ajmaline exposes its extent and distribution, which is correlated with the degree of coved ST-elevation. AES elimination by radiofrequency ablation results in ECG normalization and VT/VF noninducibility. Substrate-based ablation is effective in potentially eliminating the arrhythmic consequences of this genetic disease. Clinical Trial Registration— URL: https://clinicaltrials.gov. Unique identifier: NCT02641431.Keywords
This publication has 29 references indexed in Scilit:
- Epicardial ablation eliminates ventricular arrhythmias in an experimental model of Brugada syndromeHeart Rhythm, 2009
- Gender Differences in Clinical Manifestations of Brugada SyndromeJournal of the American College of Cardiology, 2008
- Longer Repolarization in the Epicardium at the Right Ventricular Outflow Tract Causes Type 1 Electrocardiogram in Patients With Brugada SyndromeJournal of the American College of Cardiology, 2008
- A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratificationEuropean Heart Journal, 2006
- Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more?Cardiovascular Research, 2005
- Mechanism of ST Elevation and Ventricular Arrhythmias in an Experimental Brugada Syndrome ModelCirculation, 2004
- Mapping and Ablation of Ventricular Fibrillation Associated With Long-QT and Brugada SyndromesCirculation, 2003
- Site‐Specific Arrhythmogenesis in Patients with Brugada SyndromeJournal of Cardiovascular Electrophysiology, 2003
- A New Technique to Perform Epicardial Mapping in the Electrophysiology LaboratoryJournal of Cardiovascular Electrophysiology, 1996
- Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter reportJournal of the American College of Cardiology, 1992